Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

X
Drug Profile

Cell-based Parkinson's disease therapy - Titan Pharmaceuticals

Alternative Names: Spheramine; TC-15

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Titan Pharmaceuticals
  • Developer Bayer Schering Pharma; Titan Pharmaceuticals
  • Class Antiparkinsonians; Cell therapies; Gene therapies; Neuroprotectants
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 02 Jul 2008 Suspended - Phase-II for Parkinson's disease in USA (Intrastriatal)
  • 30 Apr 2008 Four-year, follow-up efficacy and safety data from a clinical trial in patients with moderate-to-advanced Parkinson's disease released by Titan Pharmaceuticals
  • 19 Apr 2008 Pharmacodynamics data from a primate model of Parkinson's disease presented at the 60th Annual Meeting of the American Academy of Neurology (AAN-2008)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top